Vol 10: Icosapent ethyl for the treatment of severe hypertriglyceridemia.Report as inadecuate



 Vol 10: Icosapent ethyl for the treatment of severe hypertriglyceridemia.


Vol 10: Icosapent ethyl for the treatment of severe hypertriglyceridemia. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 10: Icosapent ethyl for the treatment of severe hypertriglyceridemia.
This article is from Therapeutics and Clinical Risk Management, volume 10.AbstractHypertriglyceridemia is a highly prevalent lipid abnormality and it is associated with atherosclerosis, with a growing body of evidence linking elevated triglycerides TGs with cardiovascular disease. The current major omega-3 polyunsaturated fatty acids, eicosapentaenoic acid EPA-docosahexaenoic acid DHA combination, lowers serum TGs while often increasing levels of low-density lipoprotein cholesterol. Icosapent ethyl is an omega-3 polyunsaturated fatty acid with a 96% pure ethyl ester of EPA that has been recently approved for lowering TG levels in patients with very high TGs ≥500 mg-dL, and it does so without significantly affecting serum low-density lipoprotein cholesterol. The potential benefits of omega-3 fatty acid therapy for dyslipidemias will be discussed, including the potential pros and cons of EPA alone versus the more common and readily available EPA-DHA combination therapy.



Author: Fares, Hassan; Lavie, Carl J; DiNicolantonio, James J; O'Keefe, James H; Milani, Richard V

Source: https://archive.org/







Related documents